Diagnosis and management of oral candidosis
We draw a baseline first (IGF-1, CBC, inflammatory markers, and a hormone panel depending on the stack), then build the protocol around what we find
Retatrutide has not received Health Canada approval and remains in Phase 3 clinical trials globally
New England Journal of Medicine (2025) The REDEFINE 1 Phase 3 trial was a landmark 68-week, double-blind, randomized study comparing CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg) with semaglutide alone, cagrilintide alone, and placebo in 3,417 adults with obesity or overweight without diabetes
Inside brain cells, PL is phosphorylated back to PLP